/VIRI
VIRI Stock - Virios Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$0.15+12.40%
+$0.02 (+12.40%) • Oct 8
46
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.57
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.17
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VIRI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.15 – $0.16
TARGET (TP)$0.18
STOP LOSS$0.14
RISK/REWARD1:1.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.58
52W High$26.00
52W Low$0.14
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-12,227,248,000 | $-5,446,919 | $-12,315,309 | $-15,640,940 | $-10,005,394 |
| Net Income | $-12,863,829,000 | $-5,296,015 | $-12,180,359 | $-15,960,268 | $-10,346,395 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-12.52 | $-0.28 | $-1.10 | $-1.92 | $-1.25 |
Company Overview
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
VIRIBeat Rate
79%
Last 14 quarters
Avg Surprise
+19.7%
EPS vs Estimate
Beats / Misses
11/3
Last 12 quarters
Latest EPS
$-8.20
Q4 2025
EPS Surprise History
Q2 23
+60.0%
$-0.08vs$-0.20
Q3 23
-14.3%
$-0.08vs$-0.07
Q4 23
+40.0%
$-0.06vs$-0.10
Q1 24
+33.3%
$-0.06vs$-0.09
Q2 24
+12.5%
$-0.07vs$-0.08
Q3 24
+28.6%
$-0.05vs$-0.07
Q4 24
-20.0%
$-0.06vs$-0.05
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 7, 2025 | — | $-8.20 | — | — |
Q3 2025 | Aug 6, 2025 | — | — | — | — |
Q2 2025 | May 7, 2025 | — | — | — | — |
Q1 2025 | Feb 26, 2025 | — | — | — | — |
Q4 2024 | Nov 11, 2024 | $-0.05 | $-0.06 | -20.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.07 | $-0.05 | +28.6% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-0.09 | $-0.06 | +33.3% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.10 | $-0.06 | +40.0% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.07 | $-0.08 | -14.3% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.20 | $-0.08 | +60.0% | ✓ BEAT |
Q1 2023 | Mar 14, 2023 | $-0.16 | $-0.11 | +31.3% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.49 | $-0.28 | +42.9% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.51 | $-0.44 | +13.7% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.54 | $-0.48 | +11.1% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-0.52 | $-0.54 | -3.8% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | $-0.70 | $-0.49 | +30.0% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.57 | $-0.51 | +10.5% | ✓ BEAT |
Q2 2021 | May 13, 2021 | — | $-0.37 | — | — |
Q1 2021 | Mar 18, 2021 | — | $-1.25 | — | — |
Latest News
Loading news...
Frequently Asked Questions about VIRI
What is VIRI's current stock price?
Virios Therapeutics, Inc. (VIRI) is currently trading at $0.15 per share. The stock has moved +12.40% today.
What is the analyst price target for VIRI?
No analyst price targets are currently available for this stock.
What sector is Virios Therapeutics, Inc. in?
Virios Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VIRI's market cap?
Virios Therapeutics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does VIRI pay dividends?
No, Virios Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATLN
Atlantic International Corp.
$1.30
Mkt Cap: $0.1B
BLPH
Bellerophon Therapeutics, Inc.
$0.01
Mkt Cap: $0.0B
HSTO
Histogen Inc.
$0.02
Mkt Cap: $0.0B
KERN
Akerna Corp.
$0.31
Mkt Cap: $0.0B
LFLY
Leafly Holdings, Inc.
$37.00
Mkt Cap: $0.1B
LSB
LakeShore Biopharma Co., Ltd
$0.63
Mkt Cap: $0.0B
SEEL
Seelos Therapeutics, Inc.
$0.37
Mkt Cap: $0.0B
TCBP
TC Biopharm (Holdings) Plc
$0.50
Mkt Cap: $0.0B
TFFP
TFF Pharmaceuticals, Inc.
$0.07
Mkt Cap: $0.0B
Explore stocks similar to VIRI for comparison